ACID REDUCER MAXIMUM STRENGTH NON-PRESCRIPTION TABLET

Land: Kanada

Tungumál: enska

Heimild: Health Canada

Kauptu það núna

Download Vara einkenni (SPC)
05-10-2010

Virkt innihaldsefni:

RANITIDINE (RANITIDINE HYDROCHLORIDE)

Fáanlegur frá:

MYLAN PHARMACEUTICALS ULC

ATC númer:

A02BA02

INN (Alþjóðlegt nafn):

RANITIDINE

Skammtar:

150MG

Lyfjaform:

TABLET

Samsetning:

RANITIDINE (RANITIDINE HYDROCHLORIDE) 150MG

Stjórnsýsluleið:

ORAL

Einingar í pakka:

3/8/16/24/30/60/100

Gerð lyfseðils:

OTC

Lækningarsvæði:

HISTAMINE H2-ANTAGONISTS

Vörulýsing:

Active ingredient group (AIG) number: 0115150002; AHFS:

Leyfisstaða:

CANCELLED PRE MARKET

Leyfisdagur:

2016-11-02

Vara einkenni

                                PRODUCT MONOGRAPH
ACID REDUCER MAXIMUM STRENGTH NON-PRESCRIPTION
Ranitidine Tablets, USP, 150 mg
(from Ranitidine Hydrochloride)
Histamine H
2
-receptor Antagonist
Mylan Pharmaceuticals ULC
DATE OF PREPARATION:
85 Advance Road
SEPTEMBER 28, 2010
Toronto, Ontario M8Z 2S6
CONTROL NUMBER: 141653
2
PRODUCT MONOGRAPH
ACID REDUCER MAXIMUM STRENGTH NON-PRESCRIPTION
Ranitidine Tablets, USP, 150 mg
(from Ranitidine Hydrochloride)
Histamine H
2
-receptor Antagonist
CLINICAL PHARMACOLOGY
Ranitidine is an antagonist of histamine at gastric H
2
-receptor sites. Thus, ranitidine inhibits both
basal gastric secretion and gastric acid secretion induced by
histamine, pentagastrin and other
secretagogues. Inhibition of gastric acid secretion has been observed
following intravenous,
intraduodenal and oral administration of ranitidine. This response is
dose-related, a maximum
response being achieved at an oral dose of 300 mg/day.
Pepsin secretion is also inhibited but secretion of gastric mucus is
not affected. Ranitidine does
not alter the secretion of bicarbonate or enzymes from the pancreas in
response to secretin and
pancreozymin.
Ranitidine is rapidly absorbed after oral administration, peak plasma
concentrations being
achieved within 2 to 3 hours. These plasma concentrations are not
significantly influenced by the
presence of food in the stomach at the time of the oral administration
nor by regular doses of
antacids.
Bioavailability of oral ranitidine is approximately 50%_. _Serum
protein binding of ranitidine in
man is in the range 10 to 19%. The elimination half-life is
approximately 3 hours. The principal
route of excretion is the urine (40% recovery of free and metabolized
drug in 24 hours).
There is a significant linear correlation between the dose
administered and the inhibitory effect
upon gastric acid secretion for single oral doses up to 300mg. In
healthy subjects a single 75mg
dose of ranitidine significantly reduced meal-stimulated intragastric
acidity ([H
+
] AUC)
compared with placebo. The effect of ranitidine on 
                                
                                Lestu allt skjalið
                                
                            

Leitaðu viðvaranir sem tengjast þessari vöru